FDA Pushes New Approach To Alzheimer's Drug Development

Law360, New York (February 7, 2013, 7:22 PM EST) -- The U.S. Food and Drug Administration on Thursday proposed guidance for drugmakers in developing new treatments for patients in the early stages of Alzheimer's disease, part of a federal push to develop effective treatments for the degenerative and irreversible brain disease.

Alzheimer's is the most common cause of dementia among older people, according to the FDA, and the guidance addresses possible adaptations of the current approach to drug development for the treatment of the dementia stage of the disease that may be more appropriate for clinical...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.